PROM1, prominin 1, 8842

N. diseases: 477; N. variants: 33
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE In HCC-INT, the CD133 positive rate in the INT component (83.3%) was significantly higher than the HCC component (8.3%) (P=0.001). 31661725 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines. 31042624 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype. 30959553 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE We observed that Cygb is significantly deregulated in human hepatocellular carcinoma (HCC) tissue and its decrease aggravates the growth of liver cancer stem cells (LCSCs) and increases the subpopulation of CD133(+) LCSCs. 30365183 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE <b>Conclusion:</b> The study indicates that secretory factors like TGF-β from neighboring endothelial cells may enhance expression of CD133 and impart an aggressive EMT phenotype to HBx-infected hepatoma cells in HBV induced HCC. 31069171 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Notably, docetaxel‑inhibited SOX2 expression and growth of human CD133‑expressing HCC stem cells were partially restricted following the block of the PI3K/AKT signaling pathway using the inhibitor LY294002. 30483804 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE In addition, the proportion of CD44+/CD133+ HCC cancer stem cells (CSCs) was significantly greater in cells cultured on scaffolds than in those grown in 2D cultures. 30302811 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Next, whether AQP3 acted as an oncogenic gene in HCC and maintained the stemness of CD133+ hepatoma cells were elucidated; also, a novel mechanism underlying the AQP3/STAT3/CD133 pathway in HCC was deduced. 31197130 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133<sup>+</sup> HCC. 31226288 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Both HOXA11-AS silencing and HOXA11 overexpression suppressed the self-renewal, proliferation, migration, and tumorigenicity of HCC stem cells in vivo, as evidenced by the decreased expression of cancer stem cell surface markers (CD133 and CD44) and stemness-related transcription factors (Nanog, Sox2, and Oct4). 31757938 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Furthermore, the statistical association and the diagnostic efficacies of TIPRL, LC3 and CD133 in HCC tissues were confirmed in a different IHC cohort. 31727942 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. 31066542 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Expression of the stem cell markers CD24 and CD133 in the tumors of patients with HCC was associated with greater iNOS expression and worse outcomes. 30297396 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Based on CD133 immunostaining and serum AFP levels, the HCC cases were subclassified into four subtypes, which demonstrated different clinicopathological features and varying prognoses. 29435028 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Strikingly, Anti-CD147 ILs-DOX reduced the CD133-positive fraction of HCC cells, suggesting its potential in reducing the number of HCC stem cells. 29045824 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE TRPV2 expression at protein levels revealed converse correlation with those of CD133 and CD44 in human hepatocellular carcinoma (HCC) tissue. 29906748 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Previously, we characterized CSCs in primary hepatocellular carcinoma (HCC) and identified CD133 as a CSC cell-surface marker. 30382122 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Furthermore, we revealed that the expression of liver cancer stem cell marker CD133 was also significantly increased in the residual hepatocellular carcinoma cells after RFA treatment in vivo, and was positively correlated with LC3B protein expression. iRFA also promoted CD133 protein expression in Huh-7 and SMMC7721 cell lines in vitro. 29749472 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE CD133 is served as a key biomarker to identify and characterize this subpopulation of cells in hepatocellular carcinoma (HCC). 29119708 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection. 29534065 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Annexin A3 (ANXA3) could induce progression of hepatocellular carcinoma (HCC) via promoting stem cell traits of CD133-positive cells. 29626309 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 Biomarker disease BEFREE Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM<sup>+</sup>CD133<sup>-</sup>) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1-60 µM) of LDL-DHA nanoparticles for 0-72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL-DHA nanoparticles for 3 days. 30069818 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE CD133+/CD44+ subgroup sorting from HCC cell lines and HCC tissues was used to investigate the effects of OPN knockdown on stemness. iTRAQ and MedIP-sequencing were applied to detect the protein profile and epigenetic modification of CD133+/CD44+ subgroup with or without OPN knockdown. 30064482 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE HCC cell lines with a high level of CD133 expression overexpressed EGFR, which is overexpressed in approximately 70% of conventional HCCs. 28034805 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.100 AlteredExpression disease BEFREE Although less cytotoxic, the free ligand inhibits the surface marker CD133 expression in hepatocarcinoma cells, and in HT-29 colon carcinoma. 28358339 2017